RECRUITING

CTNNA1 Familial Expansion Study

Talk to us

Conditions

Cancer Gene MutationGastric CancerBreast CancerCTNNA1Hereditary diffuse gastric cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Official Title

CTNNA1 Familial Expansion (CAFÉ) Study

Quick Facts

Study Start:2021-03-16
Study Completion:2026-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05126290

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age and older
  2. * Participants must be carrier, or a first degree relative of a carrier, of a CTNNA1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a consensus splice site variant predicted to disrupt splicing in CTNNA1. CTNNA1 loss-of-function variants do not need to be classified as pathogenic or likely pathogenic to be included.
  3. * Participants must be able to understand and read English
  4. * Participants must be able to provide informed verbal or written consent
  1. * Less than 18 years of age
  2. * Individuals who do not carry a CTNNA1 loss-of-function variant and are not a first degree relative of a CTNNA1 loss-of-function variant carrier.
  3. * Individuals who cannot speak and read English
  4. * Major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation
  5. * Unable to comply with the study procedures as determined by the study investigators or study staff

Contacts and Locations

Study Contact

Bryson W Katona, MD, PhD
CONTACT
215-349-8222
cafestudy@pennmedicine.upenn.edu
Dana Farengo Clark, MS, LCGC
CONTACT
cafestudy@pennmedicine.upenn.edu

Principal Investigator

Bryson W Katona, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Bryson W Katona, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-03-16
Study Completion Date2026-01-01

Study Record Updates

Study Start Date2021-03-16
Study Completion Date2026-01-01

Terms related to this study

Keywords Provided by Researchers

  • CTNNA1
  • Hereditary diffuse gastric cancer
  • Gastric cancer
  • Breast cancer

Additional Relevant MeSH Terms

  • Cancer Gene Mutation
  • Gastric Cancer
  • Breast Cancer